Impact of prophylaxis with rituximab on EBV-related complications after allogeneic hematopoietic cell transplantation in children.

Front Immunol · 2024 · PMC11269116 · PMID 39055711

Europe PMC DOI

hedged sentence

0.0717

closest p · 1.4× alpha

0.0717

boldest claim

The sentences

showed a trendp=0.0717so close (0.05 < p ≤ 0.1)

Prophylactic use of rituximab showed a trend toward better overall survival both in Kaplan-Meier analysis (p=0.0717) ( Figure 1H ) and the Cox model (HR=0.66; 95%CI=0.43-1.03; p=0.0687).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.